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Vaccines are recommended for adults on the basis of their 
age, prior vaccinations, health conditions, lifestyle, occupation, 
and travel. Reasons for current low levels of vaccination cover-
age for adult vaccines are multifactorial and include limited 
awareness among the public about vaccines for adults and gaps 
in incorporation of regular assessments of vaccine needs and 
vaccination into routine medical care (1–4). Updated standards 
for immunization of adults were approved by the National 
Vaccine Advisory Committee (NVAC) in September 2013 (5). 
These standards acknowledge the current low levels of vaccina-
tion coverage among adults and the role that all health-care pro-
viders, including those who do not offer all recommended adult 
vaccines in their practices, have in ensuring that their patients 
are up-to-date on recommended vaccines. NVAC recommends 
that providers assess vaccination needs for their patients at each 
visit, recommend needed vaccines, and then, ideally, offer the 
vaccine or, if the provider does not stock the needed vaccines, 
refer the patient to a provider who does vaccinate. Vaccinating 
providers should also ensure that patients and their referring 
health-care providers have documentation of the vaccination.
A recommendation by a patient’s health-care provider for 
needed vaccines is a strong predictor of patients receiving 
recommended vaccines (6,7). Other interventions to improve 
vaccination rates have been summarized in the Community 
Guide (http://www.thecommunityguide.org/vaccines/index.
html) and include systems changes, such as routine screening 
and offering of vaccines and implementation of reminder/
recall systems (8).
Because many adult patients might consult more than 
one health-care provider and also might be vaccinated at 
the workplace, pharmacy, or other location, documentation 
of vaccinations in immunization information systems (IIS) 
(i.e., vaccine registries) is important to ensure that a patient’s 
complete vaccination history is available to all of his/her pro-
viders. In addition, some vaccines require more than 1 dose 
with specified time intervals between doses (e.g., hepatitis B 
vaccine 3-dose series) or are recommended for certain adult 
populations only if adults were not vaccinated as children 
(e.g., measles-mumps-rubella [MMR] vaccine). IIS are man-
aged by state or city immunization programs; contact informa-
tion about these systems is available at http://www.cdc.gov/
vaccines/programs/iis/contacts-registry-staff.html.
The Advisory Committee on Immunization Practices (ACIP) 
annually reviews and updates the Recommended Immunization 
Schedule for Adults Aged 19 Years or Older. This schedule pro-
vides a brief summary of ACIP recommendations for the use 
of vaccines routinely recommended for adults in the form of 
two figures, footnotes for each vaccine, and a table that includes 
primary contraindications and precautions.
In October 2013, ACIP approved the Recommended 
Immunization Schedule for Adults Aged 19 Years or Older for 
2014. This schedule was also reviewed and approved by the 
American Academy of Family Physicians, the American College 
of Physicians, the American College of Obstetricians and 
Gynecologists, and the American College of Nurse-Midwives. 
The primary updates for the 2014 schedule include adding 
Recommendations for routine use of vaccines in children, ado-
lescents, and adults are developed by the Advisory Committee 
on Immunization Practices (ACIP). ACIP is chartered as a 
federal advisory committee to provide expert external advice 
and guidance to the Director of the Centers for Disease 
Control and Prevention (CDC) on use of vaccines and related 
agents for the control of vaccine-preventable diseases in the 
civilian population of the United States. Recommendations 
for routine use of vaccines in children and adolescents are 
harmonized to the greatest extent possible with recommenda-
tions made by the American Academy of Pediatrics (AAP), 
the American Academy of Family Physicians (AAFP), and 
the American College of Obstetrics and Gynecology (ACOG). 
Recommendations for routine use of vaccines in adults are 
harmonized with recommendations of AAFP, ACOG, and the 
American College of Physicians (ACP). ACIP recommenda-
tions adopted by the CDC Director become agency guidelines 
on the date published in the Morbidity and Mortality 
Weekly Report (MMWR). Additional information regard-
ing ACIP is available at http://www.cdc.gov/vaccines/acip. * Current and past ACIP member rosters are available at http://www.cdc.gov/
vaccines/acip/committee/members-archive.html.
On February 3, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/mmwr).
Morbidity and Mortality Weekly Report
MMWR / February 7, 2014 / Vol. 63 / No. 5 111
Haemophilus influenzae type b (Hib) vaccine to the figures and 
updating information in the footnote about persons for whom 
Hib vaccine is recommended; adding information to the influ-
enza vaccine footnote and contraindications table regarding the 
newly licensed recombinant influenza vaccine (RIV) and infor-
mation about the use of RIV and inactivated influenza vaccine 
(IIV) among persons with egg allergies; moving the footnote for 
pneumococcal conjugate vaccine (PCV13) recommendations 
before the pneumococcal polysaccharide vaccine (PPSV23) 
recommendations because PCV13 should be administered first 
among persons for whom both vaccines are recommended; 
and clarifying information about the timing of the second and 
third doses of human papillomavirus (HPV) vaccine, use of 
meningococcal vaccines among adults, and recommendations 
for tetanus, diphtheria, acellular pertussis (Tdap) and tetanus 
and diphtheria (Td) vaccines (9–10).
Because of space limitations, many details of the full ACIP 
recommendations for each vaccine are not included in the 
schedule, and interested health-care providers should refer 
to the full ACIP recommendations. In addition, changes in 
recommendations for specific vaccines might occur between 
annual updates to the adult immunization schedule. ACIP 
recommendations for specific vaccines are available at http://
www.cdc.gov/vaccines/hcp/acip-recs/index.html. Information 
on reporting vaccine-related adverse events is available online 
at http://www.vaers.hhs.gov or by telephone at 800-822-7967.
The full 2014 schedule is published in the Annals of Internal 
Medicine (11). This year, the figures, footnotes, and tables are 
not being published in MMWR, but will be posted and main-
tained on the CDC website at http://www.cdc.gov/vaccines/
schedules to facilitate updating the schedule during the year, if 
needed. If errors or omissions are detected after publication of the 
pediatric or adult immunization schedules, CDC posts revised 
versions. CDC encourages organizations that have previously 
relied on copying and posting portable document format (PDF) 
files of the schedules to their websites to instead use “content 
syndication” to ensure that current and accurate immunization 
schedule information appears on each organization’s website. 
This one-time step ensures that websites display current yearly 
schedules as soon as they are published or revised. Instructions 
for copying and placing syndication code are available at http://
www.cdc.gov/vaccines/schedules/syndicate.html. CDC offers 
technical assistance for organizations implementing this form 
of content syndication. For assistance, readers can complete the 
e-mail form on the CDC’s National Center for Immunization 
and Respiratory Diseases (NCIRD) web support page (http://
www.cdc.gov/vaccines/about/contact/web_problem_form.




•	 Hib vaccine recommendations were updated. The vaccine 
is recommended for certain adults at increased risk for Hib 
who have not received the Hib vaccine before. Adults who 
have had a successful hematopoietic stem cell transplant are 
recommended to receive a 3-dose series of Hib vaccine 
6–12 months after transplant regardless of prior Hib 
vaccination. Prior Hib vaccine guidance recommended that 
Hib vaccination of persons infected with human 
immunodeficiency (HIV) be considered, but updated 
guidance no longer recommends Hib vaccination of 
previously unvaccinated adults with HIV infection because 
their risk for Hib infection is low.
•	 Information on RIV and the use of RIV and IIV among 
egg-allergic patients was added to the footnote and 
indicates that RIV or IIV can be used among persons with 
hives-only allergy to eggs. RIV contains no egg protein 
and can be used among persons aged 18 through 49 years 
who have egg allergy of any severity.
•	The Td/Tdap vaccine footnote was edited to harmonize 
language used in the pediatric immunization schedule. A 
single dose of Tdap vaccine is recommended for previously 
unvaccinated persons aged 11 years or older, and a 
Td booster should be administered every 10 years 
thereafter. Pregnant women continue to be recommended 
to receive 1 dose of Tdap vaccine during each pregnancy, 
preferably during 27–36 weeks’ gestation, regardless of the 
interval since prior dose of Tdap or Td vaccine.
•	 Information was added to the HPV footnote to clarify the 
timing between the second and third doses and to harmonize 
language between the pediatric and adult immunization 
schedules; no changes in recommendations were made.
•	The HPV vaccine and the zoster vaccine footnotes were 
simplified, with removal of the bullet regarding health-care 
personnel (HCP). Being a health-care worker is not a 
specific indication for these vaccines, but they should be 
given to HCP and others who meet age and other 
indications for these vaccines. Information on HCP 
vaccination for all vaccines is available at http://www.cdc.
gov/mmwr/preview/mmwrhtml/rr6007a1.htm.
•	Because PCV13 is recommended to be administered before 
PPSV23 among persons for whom both vaccines are 
recommended, the PCV13 footnote now precedes the 
PPSV23 footnote and includes wording to remind 
providers of the appropriate order of these vaccines when 
both are indicated.
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•	 The meningococcal vaccine footnote was edited to clarify 
which persons need either 1 or 2 doses of vaccine and to 
provide greater clarity regarding which patients should receive 
the meningococcal conjugate versus the meningococcal 
polysaccharide quadrivalent vaccines.
•	No changes or minor clarifications were made to the 
MMR, hepatitis A, or hepatitis B vaccine footnotes; no 
changes in recommendations were made.
Figures
•	 For Figures 1 and 2, a row for Hib vaccine was added, and 
the PCV13 vaccine row was moved before PPSV23 as a 
reminder that PCV13 vaccines should be administered first 
among patients for whom both vaccines are recommended.
Contraindications and precautions table
•	The contraindications and precautions table was updated 
to include information on RIV, an influenza vaccine that 
contains no egg protein and is indicated for persons aged 
18 through 49 years.
•	The Hib vaccine was added to the table.
 1Immunization Services Division, National Center for Immunization and 
Respiratory Diseases, CDC; 2Division of General Pediatrics and Adolescent 
Medicine, University of North Carolina, Chapel Hill (Corresponding author: 
Carolyn B. Bridges, cbridges@cdc.gov)
References
 1. CDC. Noninfluenza vaccination coverage among adults, 2012. MMWR 
2014;63:95–102.
 2. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. 
Am J Med 2008;121:S28–35.
 3. Tan TQ, Bhattacharya L, Gerbie MV. Awareness, perceptions and 
knowledge of recommended adult vaccines among a nationwide sample 
of adult primary care providers. J Reprod Med 2011;56:301–7.
 4. Zimmmerman RK, Albert SM, Nowalk MP, Yonas MA, Ahmed F. Use 
of standing orders for adult influenza vaccine: a national survey of 
primary care physicians. Am J Prev Med 2011;40:144–8.
 5. US Department of Health and Human Services. Update on the National 
Vaccine Advisory Committee Standards for Adult Immunization 
Practice. Washington, DC: US Department of Health and Human 
Services; 2013. Available at http://www.hhs.gov/nvpo/nvac/reports/
nvacstandards.pdf.
 6. CDC. Influenza vaccination coverage among pregnant women—United 
States, 2012–13 influenza season. MMWR 2013;62:787–92.
 7. Miller BL, Kretsinger K, Euler GL, Lu P-J, Ahmed F. Barriers to early 
uptake of tetanus, diphtheria and acellular pertussis vaccine (Tdap) 
among adults—United States, 2005–2007. Vaccine 2011;29:3850–6.
 8. Community Preventive Services Task Force. Vaccinations to prevent diseases: 
universally recommended vaccinations. Community Guide systematic 
reviews. Atlanta, GA: Community Preventive Services Task Force; 2013. 
Available at http://www.thecommunityguide.org/vaccines/index.html.
 9. CDC. Prevention and control of Haemophilus influenzae type b disease: 
recommendations of the Advisory Committee on Immunization 
Practices (ACIP). MMWR 2014. In press.
 10. CDC. Prevention and control of seasonal influenza with vaccines: 
recommendations of the Advisory Committee on Immunization Practices 
(ACIP)—United States, 2013–14. MMWR 2013;62(No. RR-7).
 11. Advisory Committee on Immunization Practices Recommended 
Immunization Schedule for Adults Aged 19 Years or Older: United 
States, 2014. Ann Intern Med 2014;160:190–7.
ACIP Adult Immunization Work Group
Work Group Chair: Tamera Coyne-Beasley, MD, Chapel Hill, North Carolina. 
Work Group Members: Sandra Fryhofer, MD, Atlanta, Georgia; Kathleen Harriman, PhD, Richmond, California; Molly Howell, MPH, Bismarck, North 
Dakota; Linda Kinsinger, MD, Durham, North Carolina; Laura Pinkston Koenigs, MD, Springfield, Massachusetts; Marie-Michele Leger, MPH, PA-C, 
Alexandria, Virginia; Susan M. Lett, MD, Boston, Massachusetts; Terri Murphy MSN, Durham, North Carolina; Robert Palinkas, MD, Urbana, Illinois; 
Gregory Poland, MD, Rochester, Minnesota; Joni Reynolds, MPH, Denver, Colorado; Laura E. Riley, MD, Boston, Massachusetts; William Schaffner, MD, 
Nashville, Tennessee; Kenneth Schmader, MD, Durham, North Carolina; Jonathan L. Temte, MD, PhD, Madison, Wisconsin; Richard Zimmerman, MD, 
Pittsburgh, Pennsylvania. 
Work Group Contributors: Elizabeth Briere, MD, Atlanta, Georgia; Amy Fiebelkorn, MSN, MPH, Atlanta, Georgia; Lisa Grohskopf, MD, Atlanta, Georgia; 
Craig Hales, MD, Atlanta, Georgia; Rafael Harpaz, MD, Atlanta, Georgia; Charles LeBaron, MD, Atlanta, Georgia; Jennifer L. Liang, DVM, Atlanta, Georgia; 
Jessica MacNeil, MPH, Atlanta, Georgia; Lauri Markowitz, MD, Atlanta, Georgia; Matthew Moore, MD, Atlanta, Georgia; Tamara Pilishvili, MPH, Atlanta, 
Georgia; Sarah Schillie, MD, Atlanta, Georgia; Raymond A. Strikas, MD, Atlanta, Georgia; Walter W. Williams, MD, Atlanta, Georgia. 
Work Group Consultants: Diane Peterson, Saint Paul, Minnesota; Litjen Tan, PhD, Chicago, Illinois.
Work Group Secretariat: Carolyn B. Bridges, MD, Atlanta, Georgia.
